Drugs, Breast Cancer Suits Can Proceed
The U.S. Supreme Court Tuesday rejected a petition by several drug makers, allowing lawsuits over an alleged link between drugs and breast cancer to proceed.
The U.S. Supreme Court Tuesday rejected a petition by several drug makers, allowing lawsuits over an alleged link between drugs and breast cancer to proceed.
The three lawsuits involving more than 100 women were filed in a Minnesota court in 2008 and contended there was a link between hormone-therapy drugs used to treat menopause and breast cancer, The Wall Street Journal reported.
The suits alleged drug manufacturers had hidden the connection between the drugs and breast cancer.
The drug manufacturers, including two Pfizer Inc. subsidiaries, wanted to move the cases to consolidate them with others pending in the federal courts, the report said. Moving the cases from state to federal court would have trimmed the list of 100 state plaintiffs, the Journal said, because many of them already had filed separately in federal court.
The drug makers alleged that the Minnesota suits had fraudulently tried to keep the cases in state court.
Eventually, a
Related News
-
News Panaxia's medical cannabis facility in Malta gains EU-GMP standard
This second facility gives the company a significant power multiplier for export capacity and geographical reach -
News CPhI Discover: Remote excipient audits are on the increase, but we must do more to develop novel excipients
Ahead of the session, Value Added Excipients to Unlock the Potential of APIs, at CPhI Discover on Thursday 18th May – global pharma’s largest ever virtual gathering – we spoke with one of the speakers, Dr Iain Moor... -
News Pharma Explained: What is Quality Risk Management & cGMPs?
Need clarity on determining your QA from your QbD and your cGMPs? You’re not alone! In our new Pharma Explained series from CPhI, we bring you clear cut definitions from industry experts on a myriad of Pharma Terms, delivered in bitesize video presenta... -
News Former FDA Commissioner lays out roadmap for building out excess capacity to deal with pandemic situations
Dr Scott Gottlieb shares insights into COVID-19 vaccine development, the upcoming US election and pharma pricing at the CPhI Festival of Pharma -
News Successful MHRA regulatory inspection for Scottish CMO Symbiosis
Inspection conducted remotely using video-conferencing and an online private document sharing platform. -
News Mylan and development partner win significant EPO ruling related to Copaxone
Decision clears legal pathway to expand access for patients living with multiple sclerosis in markets across Europe. -
News COVID-19 ushers in age of digital, flexible EU pharmaceutical regulation
The pandemic that has swept over the world in 2020 has caused huge disruption to the European pharmaceutical industry's regulatory procedures and supply chain management. But the crisis has also provided a platform for a learning process for the sy... -
News Europe's CHMP recommends suspension of medicines tested by Panexcell over flawed studies
The European Medicines Agency's human medicines committee (CHMP) has recommended the suspension of European marketing authorizations of generic medicines tested by Panexcell Clinical Laboratories at its site in Mumbai, India, citing irregularities in h...
Position your company at the heart of the global Pharma industry with a CPhI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPhI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance